Abstract
In 2008, the Secretary of National Medicines and Poisons Board (NMPB) carried out a study that measured prices of drugs marketed in Sudan. The unpublished study reported that 23% in public sector and 38% in private sector of studied drugs were higher 10 times than international prices. The importance of the study that it's results in turn were used by Sudanese health policymaker as evidence that policies are needed to contain drug prices. In 2010, the NMPB issued a decree of medicine pricing and according to its regulations registered medicines in Sudan have been revised, and the importers were asked to reduce their prices between 15% and 80% of their registered cost and freight prices. In this review, we criticized and commented only on some conclusions and recommendations without going deeply in the methodological flaws that study suffer from.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
